RTTNews BiotechQwen · 实盘不做把握 2/10不做原因:标的无直接敞口
北京时间·🕒 发布 19:51:05·⟳ 抓取 20:00:49 +9m44s·⚡ 决策 08-27 20:02:23 +1m34s·61.2 天前
第一三共CD25靶向ADC药物DS1025完成首例患者给药，进入I期临床
Phase 1首例给药是生物医药最低影响的临床里程碑，距收入兑现7-10年以上；第一三共为超大市值药企（万亿日元级），单一早期管线资产相对市值无增量；CD25为全新靶点、全球无同类获批，无法映射到有实质敞口的跨市场标的。经验megacap-soft-catalyst-materiality和biopharma-clinical-regulatory-rights-crossmarket均指向不做。
📄 原文RTTNews Biotech↗ 原文
Daiichi Sankyo Doses First Patient In Phase 1 Trial Of Novel CD25-Directed ADC DS1025
Daiichi Sankyo (4568.T) announced that the first patient has been dosed in a first-in-human Phase 1 trial evaluating DS…
不做 第一三共（4568.JP）
超大市值药企（万亿日元级）的I期首例给药是最低影响的管线里程碑：无收入/订单/指引变化，距商业化7-10年以上，相对市值增量趋近于零。CD25为全新靶点，无跨市场可映射标的。属于megacap软催化默认不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
第一三共宣布DS1025（CD25靶向ADC）I期首例给药。状态迁移仅为临床前→I期，无疗效/安全性数据、无收入影响、无监管里程碑。第一三共市值为万亿日元级别，9个ADC管线中新增一个I期资产对估值无可测量增量。CD25为全新靶点，全球无同类获批产品，不存在可映射的同靶点竞品或供应链受益标的。结论：软催化+超大市值+最早期阶段=无可交易edge。
🔎 新鲜度:最早出现 2026-08-27 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:先例研究不适用于无交易价值的Phase 1首例给药事件
方向:无需先例——事件本身不具备交易价值
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- fetch_decision_experience 成功 stock_tools HTTP · 1,691 ms
{
原文全文
展开原文 · 2,099 字
Daiichi Sankyo (4568.T) announced that the first patient has been dosed in a first-in-human Phase 1 trial evaluating DS1025, a potential first-in-class CD25-directed antibody-drug conjugate (ADC), in patients with advanced or metastatic solid tumors.
About DS1025
DS1025 is designed to target CD25, a protein highly expressed on regulatory T cells, which can suppress immune responses against cancer.
The investigational ADC uses an immuno-oncology-optimized cytotoxic payload designed to deplete immunosuppressive T cells in the tumor microenvironment and potentially enhance the immune system's ability to detect and destroy cancer cells.
Currently, no CD25-directed ADCs have been approved for any cancer indication.
Phase 1 Trial
The multicenter, open-label, dose-escalation study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of DS1025 in patients whose disease has progressed after at least one prior line of standard therapy.
Primary endpoints include safety, tolerability, dose-limiting toxicities and adverse events.
The study will also assess pharmacokinetics and immunogenicity, with exploratory endpoints including overall response rate, duration of response and time to response.
The trial is expected to enroll up to 45 patients across multiple sites in Asia and Europe.
Next Steps
The initiation of the Phase 1 trial expands Daiichi Sankyo's oncology pipeline and its portfolio of nine ADCs in clinical development, as the company continues advancing novel antibody-drug conjugates across multiple cancer targets.
4568.T has traded between JPY 2,390.00 and JPY 4,178.00 over the last year.
The stock is closed Thursday's trading at JPY 2,886.50 down 0.47%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.
About DS1025
DS1025 is designed to target CD25, a protein highly expressed on regulatory T cells, which can suppress immune responses against cancer.
The investigational ADC uses an immuno-oncology-optimized cytotoxic payload designed to deplete immunosuppressive T cells in the tumor microenvironment and potentially enhance the immune system's ability to detect and destroy cancer cells.
Currently, no CD25-directed ADCs have been approved for any cancer indication.
Phase 1 Trial
The multicenter, open-label, dose-escalation study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of DS1025 in patients whose disease has progressed after at least one prior line of standard therapy.
Primary endpoints include safety, tolerability, dose-limiting toxicities and adverse events.
The study will also assess pharmacokinetics and immunogenicity, with exploratory endpoints including overall response rate, duration of response and time to response.
The trial is expected to enroll up to 45 patients across multiple sites in Asia and Europe.
Next Steps
The initiation of the Phase 1 trial expands Daiichi Sankyo's oncology pipeline and its portfolio of nine ADCs in clinical development, as the company continues advancing novel antibody-drug conjugates across multiple cancer targets.
4568.T has traded between JPY 2,390.00 and JPY 4,178.00 over the last year.
The stock is closed Thursday's trading at JPY 2,886.50 down 0.47%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。